Clinical Trial

AI Multimodal Model for Predicting CRPC Progression Risk

Study acronym: AI-MM_CPRC
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
This study aims to develop an artificial intelligence model to predict which patients with advanced prostate cancer are at higher risk of developing castration-resistant prostate cancer (CRPC), a more severe form of the disease. The study will use pre-treatment MRI images, biopsy pathology slides, and clinical data collected from patients who received either hormone therapy (ADT) or radical prostatectomy surgery. By integrating these different types of data, the AI model is designed to help doctors identify high-risk patients earlier, personalize treatment plans, and ultimately improve patient outcomes. This is a multicenter, retrospective study that will analyze data from over 500 patients with at least 24 months of follow-up. The performance of the model will be evaluated using standard accuracy metrics.
Trial Details
NCT Number NCT07658573
Lead Sponsor Guangxi Medical University
Conditions Prostate Cancer, Castration-Resistant Prostate Cancer
Enrollment 500 participants
Start Date 2025-06-01
Primary Completion 2028-06-01 (estimated)
Study Completion 2028-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-22